CAG
DFTX

Csenge Advisory Group’s Definium Therapeutics DFTX Stock Holding History

Csenge Advisory Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-807
Closed -$42K – 675
2021
Q4 		$42K Sell
807
-167
-17% -$5.33K ﹤0.01% 541
2021
Q3 		$34K Buy
974
+167
+21% +$7.22K ﹤0.01% 569
2021
Q2 		$42K Buy
+807
New +$42.4K ﹤0.01% 544

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Csenge Advisory Group's DFTX Position: Q1 2022 in Review

Csenge Advisory Group sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 807 shares — an estimated $42K sold.

Csenge Advisory Group first reported a position in DFTX in Q2 2021 and held it in 3 quarters. The position peaked at $42K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Csenge Advisory Group reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Csenge Advisory Group sold 807 Definium Therapeutics shares in Q1 2022, an estimated $42K.
  • Csenge Advisory Group first reported a position in Definium Therapeutics in Q2 2021 and held it in 3 quarters.
  • Csenge Advisory Group's Definium Therapeutics position peaked at $42K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Csenge Advisory Group's 13F filing for Q1 2022, filed 9 May 2022.